The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1387
April 2, 2012
View Complete Issue         Table of Contents 2019 
Ruxolitinib (Jakafi) for Myelofibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ruxolitinib (Jakafi) for Myelofibrosis
April 2, 2012 (Issue: 1387)
The FDA has approved ruxolitinib (Jakafi – Incyte), a janus-associated kinase (JAK) inhibitor, for treatment of myelofibrosis. Jakafi is the first JAK inhibitor to be approved for any indication and the only drug approved for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ruxolitinib (Jakafi) for Myelofibrosis
Article code: 1387c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.